Bispecific antibodies against the B-cell maturation antigen (BCMA) exhibit potent single-agent activity in multiple myeloma (MM), yet not all patients respond with a cumulated primary resistance rate of up to 40% of patients across all trials and agents [1]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.